Study summary

Sparsentan lowered protein in the urine more than irbesartan, though kidney function decline was similar

DUPLEX trial (sparsentan) · 371 people, phase 3 · Published December 2023, New England Journal of Medicine

42.0%partial remission of proteinuria at 36 weeks, vs 26.0%

What was tested

Sparsentan, a daily pill that blocks both endothelin and angiotensin receptors, against irbesartan (a standard blood pressure drug that protects the kidneys), for 108 weeks in people aged 8 to 75 with FSGS.

What they found

What it means

Basis for the first FDA approval for FSGS in April 2026.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.